Skip to Content
 

VICC toll-free number 1-877-936-8422

Clinical Trials for Bladder Cancer

8 Open Trials

    Trial Type Protocol No. &
    Open Date
    Summary

    Basic Science

    VICCURO1322

    03/28/2014

    Vanderbilt Assessment of Shed ALCAM in Urogenital Cancers (VanSA)

    Treatment

    VICCMD1605

    03/28/2017

    Phase 1/2a Study of Double-Immune Suppression Blockade by Combining a CSF1R Inhibitor (PLX3397) with an Anti-PD-1 Antibody (Pembrolizumab) to Treat Advanced Melanoma and Other Solid Tumors

    Treatment

    VICCGI15126

    05/03/2016

    A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors

    Treatment

    ECOGUROS1314

    01/18/2016

    A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer

    Treatment

    VICCPHI1588

    11/27/2015

    A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of INCB Combinations in Advanced Solid Tumors

    Treatment

    VICCHEMP1558

    10/09/2015

    A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies

    Treatment

    ECOGUROEA8141

    08/27/2015

    A Prospective Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery for Patients with High Grade Upper Tract Urothelial Carcinoma

    Treatment

    VICCMD1403

    06/02/2014

    An Open Label, Phase II Study of Neratinib in Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification


    Print this page for your doctor